1. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. (March 2019) Authors: Pearson, Andrew D.J.; Scobie, Nicole; Norga, Koenraad; Ligas, Franca; Chiodin, Davy; Burke, Amos; Minard-Colin, Veronique; Adamson, Peter; Marshall, Lynley V.; Balakumaran, Arun; Benettaib, Bouchra; Bhargava, Pankaj; Bollard, Catherine M.; Bolotin, Ellen; Bomken, Simon; Buechner, Jochen; Burkhard... Journal: European journal of cancer Issue: Volume 110(2019) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort. Issue 12 (7th October 2022) Authors: Ri, Masaki; Suzuki, Kenshi; Ishida, Tadao; Kuroda, Junya; Tsukamoto, Taku; Teshima, Takanori; Goto, Hideki; Jackson, Carolyn C.; Sun, Huabin; Pacaud, Lida; Fujikawa, Ei; Yeh, Tzu‐Min; Hatayama, Tomoyoshi; Aida, Kensuke; Sunagawa, Yoshihiro; Iida, Shinsuke Journal: Cancer science Issue: Volume 113:Issue 12(2022) Page Start: 4267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022) Authors: Martin, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D; Htut, Myo; Stewart, A Keith; Hari, Parameswaran; Berdeja, Jesus G; Usmani, Saad Z; Yeh, Tzu-Min; Olyslager, Yunsi; Goldberg, Jenna D; Schecter, Jordan M; Madduri, Deepu; Jackson, Carolyn C; Deraedt, William; Gries, Katharine S; Fastenau, John... Journal: Lancet Issue: Volume 9:Issue 12(2022) Page Start: e897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (3rd October 2021) Authors: Martin, Tom; Usmani, Saad Z.; Schecter, Jordan M.; Vogel, Martin; Jackson, Carolyn C.; Deraedt, William; Tian, Hong; Yeh, Tzu-min; Banerjee, Arnob; Pacaud, Lida; Garrett, Ashraf; Haltner, Anja; Cameron, Chris; Van Sanden, Suzy; Diels, Joris; Valluri, Satish; Samjoo, Imtiaz A. Journal: Current medical research and opinion Issue: Volume 37:Number 10(2021) Page Start: 1779 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. (3rd October 2022) Authors: Costa, Luciano J.; Hari, Parameswaran; Berdeja, Jesus G.; De Stefano, Valerio; Gay, Francesca; Hooper, Becky; Bartlett, Meaghan; Haltner, Anja; Rosta, Emily; Kumar, Shaji; Martin, Thomas; Mateos, Maria-Victoria; Moreau, Philippe; Usmani, Saad Z.; Olyslager, Yunsi; Schecter, Jordan M.; Roccia, Tit... Journal: Current medical research and opinion Issue: Volume 38:Number 10(2022) Page Start: 1759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (2nd January 2023) Authors: Martin, Tom; Usmani, Saad Z.; Schecter, Jordan M.; Roccia, Tito; Jackson, Carolyn C.; Deraedt, William; Yeh, Tzu-min; Banerjee, Arnob; Pacaud, Lida; Garrett, Ashraf; Bartlett, Meaghan; Haltner, Anja; Van Sanden, Suzy; Diels, Joris; Valluri, Satish; Samjoo, Imtiaz A. Journal: Current medical research and opinion Issue: Volume 39:Number 1(2023) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗